DAPT Score Calculator — Dual Antiplatelet Therapy
The DAPT score, validated in the landmark 2016 DAPT trial (Yeh et al., JAMA 2016), predicts whether a patient who completed 12 months of dual antiplatelet therapy after PCI will have a net ischemic benefit or net harm from continuing DAPT beyond 12 months. Score ≥ 2 indicates prolonged DAPT is beneficial; score < 2 suggests bleeding risk outweighs benefit.
Age group
Current cigarette smoking
Diabetes mellitus
MI at presentation
Prior PCI or prior MI
Paclitaxel-eluting stent
Stent diameter < 3 mm
Congestive heart failure or LVEF < 30%
Vein graft stent PCI
Prolonged DAPT NOT recommended (<2): excess bleeding risk outweighs ischemic benefit
- 1
Age group contribution
-1Age < 65 → 0, age 65–74 → −1, age ≥ 75 → −2. - 2
High-weight items (MI at presentation +3, CHF/LVEF +2, vein graft +2)
0 + 0 + 0 = 0 - 3
Other items (smoking, DM, prior PCI/MI, paclitaxel stent, stent < 3 mm)
0 + 0 + 0 + 0 + 0 = 0 - 4
DAPT Score
-1 + 0 + 0 = -1Score ≥ 2 favours prolonged DAPT; score < 2 does not.
How does this calculator work?
The DAPT score uses 9 weighted clinical variables (range −2 to +10) to determine whether prolonged dual antiplatelet therapy (>12 months) after PCI has net benefit. Score ≥ 2 favours prolonged DAPT (ischemic benefit > bleeding risk); score < 2 does not. Largest positive weight is MI at presentation (+3). Published: Yeh et al., JAMA 2016.
Formula
How this is calculated
The DAPT score was derived and validated in the DAPT Study, a randomised trial of 11,648 patients who remained event-free at 12 months after PCI with a drug-eluting stent. It assigns integer weights to nine clinical variables: age ≥ 75 subtracts 2 points (higher bleeding risk); age 65–74 subtracts 1 point; age < 65 adds 0. MI at presentation adds the largest positive weight (+3) because patients with MI at index PCI gain the most ischemic protection. Congestive heart failure / LVEF < 30% and vein graft PCI each add +2. All other positive factors add +1.
A score of ≥ 2 identifies patients in whom prolonged DAPT (18–30 months in the trial) reduced the risk of MI and stent thrombosis more than it increased major bleeding. A score < 2 identifies patients whose bleeding risk reduction from stopping DAPT exceeds the ischemic benefit of continuing. The cut-point of 2 was chosen to maximise net clinical benefit (ischemic events minus bleeding events) in the validation cohort.
Limitations: the score was developed in the era of first- and second-generation DES and may not fully apply to newer stent platforms. It does not account for bleeding history, oral anticoagulant use, frailty or patient preference, all of which are important in clinical decision-making. Use alongside current ACC/AHA and ESC guidelines.
Frequently asked questions
The DAPT (Dual Antiplatelet Therapy) Study was a multicentre randomised controlled trial that enrolled patients after PCI with DES, randomised them at 12 months to continued thienopyridine + aspirin vs. placebo + aspirin for a further 18 months, and published results in the New England Journal of Medicine in 2014. The DAPT score was derived from this dataset and published in JAMA in 2016 by Yeh et al.
No — the score is a decision-support tool, not a mandate. Contraindications to prolonged DAPT (active bleeding, planned surgery, high-risk of falls, inability to comply) override a favourable score. Conversely, a high-risk clinical picture may prompt shared-decision discussion even with a score < 2. Always interpret within the full clinical context and current guidelines.
No. The DAPT score was derived from patients on aspirin + thienopyridine only. Patients requiring oral anticoagulation (AF, VTE, mechanical valves) should follow separate triple-therapy duration guidelines (e.g. ESC 2023 AFPCI guidance), which are based on bleeding and stroke risk rather than the DAPT score.
TG we-Calculate Editorial Team. (2026). DAPT Score Calculator — Dual Antiplatelet Therapy [Online calculator]. TG we-Calculate. https://we-calculate.com/calculator/dapt-calculator
TG we-Calculate Editorial Team. "DAPT Score Calculator — Dual Antiplatelet Therapy." TG we-Calculate. 2026. https://we-calculate.com/calculator/dapt-calculator.
TG we-Calculate Editorial Team, "DAPT Score Calculator — Dual Antiplatelet Therapy," TG we-Calculate, 2026. [Online]. Available: https://we-calculate.com/calculator/dapt-calculator
@misc{wecalculate_dapt_calculator, title = {DAPT Score Calculator — Dual Antiplatelet Therapy}, author = {{TG we-Calculate Editorial Team}}, howpublished = {\url{https://we-calculate.com/calculator/dapt-calculator}}, year = {2026}, note = {TG we-Calculate} }
Did this calculator help you?